PH Pharma, an innovative new drug research and development company, recently received final approval from the UK and Ireland authorities for the Phase 2 Clinical Trial to develop PHP-303 as the treatment for alpha-1 antitrypsin deficiency.
(For more information, please refer to the link below)
https://www.edaily.co.kr/news/read?newsId=02745366625637392